Related Articles
Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
Tumour vaccines expressing IL-2, CD80, and IL-2 plus CD80 gene
Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines
MHC class II genotype- and MHC class I and II phenotype-related parameters in sporadic colorectal cancer
CYTOKINE GENE-MODIFIED VACCINES FOR IMMUNOTHERAPY OF CANCER (REVIEW)